Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

October 12, 2022

Primary Completion Date

March 11, 2025

Study Completion Date

March 11, 2025

Conditions
Allergy, Peanut
Interventions
DRUG

remibrutinib

oral tablets

DRUG

placebo

oral tablets

Trial Locations (23)

10032

Columbia University Irving Medical, New York

20010

Childrens National Hospital, Washington D.C.

20815

Institute for Asthma and Allergy PC, Chevy Chase

21287

Johns Hopkins Hospital, Baltimore

35209

Allervie Clinical Research, Birmingham

40217

Family Allergy and Asthma, Louisville

40509

Bluegrass Allergy Research ., Lexington

43213

CR Services Acquisition US Main center, Columbus

48109

University of Michigan Clinical Trials Office, Ann Arbor

60305

Asthma and Allergy Center of Chicago S C, River Forest

61761

Midwest Allergy Sinus Asthma SC, Normal

72202

Arkansas Children's Hospital, Little Rock

74136

Vital Prospects Clinical Research Institute, Tulsa

79924

Western Sky Medical Research, El Paso

80230

Colorado Allergy and Asthma Ctr PC, Denver

80907

Asthma and Allergy Associates P C, Colorado Springs

83706

Treasure Valley Medical Research, Boise

84093

Allergy Associates of Utah, Sandy City

90025

California Allergy and Asthma Medical Group, Los Angeles

94598

Allergy and Asthma Clin Res Inc, Walnut Creek

98115

Seattle Allergy and Asthma Rsch, Seattle

02114

Massachusetts General Hospital, Boston

08009

CenExel HRI, Berlin

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY